BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/30/2021 10:10:27 AM | Browse: 789 | Download: 2109
 |
Received |
|
2020-10-26 08:01 |
|
Peer-Review Started |
|
2020-10-26 08:01 |
|
First Decision by Editorial Office Director |
|
2020-11-03 00:14 |
|
Return for Revision |
|
2020-11-03 00:14 |
|
Revised |
|
2020-11-12 08:48 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-11-17 12:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-11-21 05:41 |
|
Articles in Press |
|
2020-11-21 05:41 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-01-06 01:37 |
|
Publish the Manuscript Online |
|
2021-01-30 10:10 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jonathan Wong-Chong, Maureen Bernadach, Angeline Ginzac, Hugo Veyssière and Xavier Durando |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hugo Veyssière, N/A, N/A, N/A, Division de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, 58 rue Montalembert, Clermont-Ferrand 63011, France. hugo.veyssiere@clermont.unicancer.fr |
| Key Words |
Thymic epithelial carcinoma; Programmed death-ligand 1 negative; Pembrolizumab; Immune checkpoint; Metastasis; Case report |
| Core Tip |
Thymic epithelial carcinomas are rare and have poor prognosis. The overall 5-year survival rate for patients with thymic carcinoma is about 30%–50%. We present the case of a 45-year-old Caucasian male who presented with hepatalgia and a cervical mass, and was diagnosed with programmed death-ligand 1-negative metastatic thymic carcinoma. The patient underwent pretreatment with platinum-based chemotherapy, after which pembrolizumab was administered as salvage therapy and complete metabolic response was achieved. |
| Publish Date |
2021-01-30 10:10 |
| Citation |
Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, Durando X. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World J Clin Cases 2021; 9(5): 1139-1147 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i5/1139.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i5.1139 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
